US2018316309A1PendingUtilityA1

Sns-595 and methods of using the same

66
Assignee: SUNESIS PHARMACEUTICALS INCPriority: Mar 15, 2004Filed: Apr 27, 2018Published: Nov 1, 2018
Est. expiryMar 15, 2024(expired)· nominal 20-yr term from priority
Inventors:Michelle ArkinJennifer HydeDuncan WalkerJasmin Wright
A61P 43/00A61P 35/00A61P 7/06A61P 35/02A61P 1/08A61P 13/08A61K 38/15A61K 31/52A61K 31/395A61K 31/7068A61K 31/704A61K 31/282A61K 31/407F24S 10/70A61K 38/1816A61K 31/4745A61K 31/44A61K 31/4375A61K 31/7048F24S 50/40A61K 31/513F24S 80/60Y02E10/52A61K 31/337A61K 41/00A61K 31/555A61K 31/519C07D 471/04Y02E10/40A61K 31/585A61K 47/12A61K 45/06H02S 40/38F24S 60/30H01L 31/0547A61K 33/24A61K 9/0019H01L 31/052F24J 2/402A61K 2300/00H02S 40/44F24J 2/51H10F 77/488H10F 77/63Y02E70/30Y02E10/60Y02E10/44
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to SNS-595 and methods of treating cancer using the same.

Claims

exact text as granted — not AI-modified
1 - 25 . (canceled) 
     
     
         26 . A method for treating cancer comprising administering to a human patient having cancer (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in a dose of about 10 mg/m 2 -100 mg/m 2  and a therapeutically effective amount of a second agent selected from an agent that inhibits nonhomologous end joining repair, an apoptosis enhancing agent, an alkylating agent, an anti-neoplastic antibiotic, a platinum coordination complex and a topoisomerase II inhibitor. 
     
     
         27 . The method of  claim 26 , wherein the dose is about 30 mg/m 2 -75 mg/m 2 . 
     
     
         28 . The method of  claim 26 , wherein the dose is about 40 mg/m 2 -80 mg/m 2 . 
     
     
         29 . The method of  claim 26 , wherein the dose is about 50 mg/m 2 -90 mg/m 2 . 
     
     
         30 . The method of  claim 26 , wherein the second agent is the agent that inhibits nonhomologous endjoining repair which is a DNA-PK inhibitor. 
     
     
         31 . The method of  claim 26 , wherein the second agent is the agent that inhibits nonhomologous endjoining repair which is a ligase IV inhibitor. 
     
     
         32 . The method of  claim 26 , wherein the second agent is the apoptosis enhancing agent which is a caspase-9 activator, a caspase-3 activator or a Hsp90 inhibitor. 
     
     
         33 . The method of  claim 26 , wherein the second agent is the alkylating agent is which is a nitrogen mustard, an alkyl sulfonate, a nitrosourea, or a triazene 
     
     
         34 . The method of  claim 26 , wherein the second agent is the anti-neoplastic antibiotic which is bleomycin, dactinomycin, daunorubicin or doxorubicin. 
     
     
         35 . The method of  claim 26 , wherein the second agent is the platinum coordination complex which is carboplatin, cisplatin or oxaliplatin. 
     
     
         36 . The method of  claim 26 , wherein the cancer is leukemia.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.